(-)-Ropivacaine-d7 is intended for use as an internal standard for the quantification of (-)-ropivacaine by GC- or LC-MS. (-)-Ropivacaine is a potent and reversible blocker of sodium channels in nerve fibers.1 In vivo, (-)-ropivacaine induces complete impairment of proprioception, motor function, and nociception in the hindleg of rats when 100 μL of an 8 mM solution is injected percutaneously into the sciatic nerve.2 (-)-Ropivacaine depresses myocardial contractile force in isolated rat hearts less potently than (±)-ropivacaine, as well as (-)- and (±)-bupivacaine .3 Formulations containing (-)-ropivacaine have been used as local anesthetics during surgery and childbirth.
1.Hansen, T.G.Ropivacaine: A pharmacological reviewExp. Rev. Neurother.4(5)781-791(2004) 2.Sinnott, C.J., and Strichartz, G.R.Levobupivacaine versus ropivacaine for sciatic nerve block in the ratReg. Anesth. Pain Med.28(4)294-303(2003) 3.Pinotti, M.F., Hepner, A., Campos, D.H., et al.Myocardial contractility impairment with racemic bupivacaine, non-racemic bupivacaine and ropivacaine. A comparative studyActa Cir. Bras.30(7)484-490(2015)